P-glycoprotein-based drug-drug interactions: Preclinical methods and relevance to clinical observations

Archives of Pharmacal Research

Volumn 27, Issue 2, 2004, Pages 127-135

  Aszalos, Adorjan ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Clinical studies; Drug drug interactions; P Glycoprotein; Polypharmacy; Preclinical studies

Indexed keywords

GLYCOPROTEIN P;

CELL LINE; DRUG INTERACTION; DRUG THERAPY; HUMAN; PHYSIOLOGY; REVIEW;

CELL LINE; DRUG INTERACTIONS; DRUG THERAPY; HUMANS; P-GLYCOPROTEIN;

EID: 4644296309     PISSN: 02536269     EISSN: 02536269     Source Type: Journal    
DOI: 10.1007/BF02980095     Document Type: Review

References (39)

1. Ambudkar, S., Drug-stimulated ATPase activity in crude membranes of human MDR1-transfected mammalian cells. Meth. Enzymol., 292, 504-514 (1998).
2. Booth, C. L., Brouwer, K. R., and Brouwer, K. L., Effect of multidrug resistance modulators on the hepatobiliary disposition of doxorubicin in the isolated perfused rat liver. Cancer Res., 58, 3641-3648 (1998).
3. Borst, P. and Elferik, R. O., Mammalian ABC transporters in health and disease. Ann. Rev. Biochem., 71, 537-592 (2002).
4. De Lannoy, I. A. M., Mandin, R. S., and Silverman, M., Renal secretion of vinblastine, vincristine and colchicine in vivo. J. Pharmacol. Exp. Ther., 268, 388-395 (1994).
5. Dorovini-Zis, K., Prameya, R., and Bowman, P. D., Culture and Characterization of microvascular endothelial cells derived from human brain. Lab. Invest., 64, 425-436 (1991).
6. Floren, L. C., Bekersky, I., Benet, L. Z., Mekki, Q., Dressler, D., Lee, J. W., Roberts, J. P., and Herbert, M. F., Tacrolimus oral bioavailability doubles with coadministration of ketaconazole. Clin. Pharmacol. Ther., 62, 41-49 (1997).
7. Fromm, M. F., Kim, R. B., Stein, C. M., Wilkinson, G. R., and Roden, D. M., Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine. Circulation, 99, 552-557 (1999).
8. Glynn, S. and Yazdanian, M., In vitro blood-brain barrier permeability of nevirapine compared to other HIV antiretroviral agents. J. Pharma. Sci., 87, 306-310 (1998).
9. Gottesman, M. M., Foho, T., and Bates, S. E., Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer, 2, 48-58 (2002).
10. Greiner, B., Eichelbaum, M., Fritz, P., Kreichgauer, H. P., von Richter, O., Zundler, J., and Kroemer, H. K., The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J. Clin. Invest., 104, 147-153 (1999).
11. Gupta, S., Kim, C. H., Tsuruo, T., and Gollapudi, S., Preferential expression and activity of multidrug resistance gene 1 product (P-glycoprotein), a functionally active efflux pump, in human CD8+ cells: a role in cytotoxic effector function. J. Clin. Immunol., 12, 13-20 (1992).
12. Hebert, M. F. and Lam, A. V., Diltiazem increases tacrolimus concentration. Ann. Pharmacother., 33, 680-682 (1999).
13. Hegmann, E. J., Bauer, H. C., and Kerbel, R. S., Expression and functional activity of P-glycoprotein in cultured cerebral capillary endothelial cells. Cancer Res., 52, 6969-6969 (1992).
14. Hoffmeyer, S., Burk, O., Von Richter, O., Arnold, H. P., Brockmoller, J., Johne, A., Cascorli, I., Gerloff, T., Roots, I., Eichelbaume, M., and Brinkmann, U., Functional polymorphism of the human multidrug-resistant gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci., 97, 4373-3478 (2000).
15. Horio, M., Chin, K. V., Currier, S. J., Goldenberg, S., Williams, C., Pastan, I., Gottesman, M., and Handler, J., Transepithelial transport of drugs by the multidrug transporter in cultured Madin-Darby canine kidney cell epithelia. J. Biol. Chem., 264, 14880-14884 (1989).
16. Ibrahim, S., Peggins, J., Knapton, A., Licht, T., and Aszalos, A., Influence of beta-adrenergic antagonists, H1-receptor blockers, analgesics, diuretics and quinolone antibiotics on the cellular accumulation of the anticancer drug, daunorubicine: P-glycoprotein modulation. Anticancer Res., 21, 847-856 (2001).
17. 2+ channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation. J. Pharmacol. Exp. Ther., 295, 1276-1283 (2000).
18. Kamimoto, Y., Gatmaitan, Z., Hsu, J., and Arias, I. M., The function of Gp170, the multidrug resistance gene product, in rat liver canalicular membrane vesicles. J. Biol. Chem., 264, 11693-11698 (1989).
19. Karlson, J., Kuo, S.-M., Ziemniak, J., and Artursson, P., Transport of celiprolol across human intestinal (Caco-2) cells: mediation of secretion by multiple transporters including P-glycoprotein. Br. J. Pharmacol., 10, 1009-1016 (1993).
20. Kim, R. B., Fromm, M. F., Wandel, C., Leake, B., Wood, A. J. J., Roden, D. M., and Wilkinson, G. R., The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest., 101, 289-294 (1998).
21. Klimecki, W. T., Futscher, B. W., Grogen, T. M., and Dalton, W. S., P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood, 83, 2451-2458 (1994).
22. Lazarou, J., Pomeranz, B. H., and Corey, P. N., Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA, 279, 1200-1205 (1998).
23. Mayer, U., Wagenaar, E., Beijnen, J. H., Smit, J. W., Meijer, D. K. van Aspen, J., Borst, P., and Schinkel, A. H., Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by mdr 1a P-glycoprotein. Br.J. Pharmacol., 119, 1038-1044 (1996).
24. Malorni, W., Lucia, M. B., Rainaldi, G., Cauda, R., Cianfriglia, M., Donelli, G., and Ortona, L., Intracellular expression of P-170 glycoprotein in peripheral blood mononuclear cell subsets from healthy donors and HIV-infected patients. Haematologica, 83, 13-20 (1988).
25. Muruganandam, A., Herx, M. L., Monette, R., Durkin, J. P., and Stanimirovic, D. B., Development of immortalized human cerebromicrovascular endothelial cell line as an in vitro model of the human blood-brain barrier. FASEB J., 11, 1187-1197 (1997).
26. Pastan, I., Gottesman, M. M., Ueda, K., Lovelace, E., Rutherford, A., and Willingham, M., A retrovirus carrying MDR1 cDNA confers multiple drug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc. Natl. Acad. Sci., 85, 9486-9490 (1988).
27. Rao, V. V., Dahlheimer, J. L., Bardget, M. E., Snyder, A. Z., Finch, R. A., Sartorelli, A. C., and Piwnica-Worms, D., Choroid plexus epithelial expression of MDR1 P-glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc. Natl. Acad. Sci., 96, 3900-3905 (1999).
28. Sachs, M. K., Blanchard, L. M., and Green, P. J., Interaction of itraconazole and digoxin. Clin.Inf. Dis., 16, 400-403 (1993).
29. Schinkel, A. H., Smit, J. J. M., van Tellingen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., van der Valk, M. A., Robanus-Maandag, E. C., te Riele, H. P. J., Berns, A. J. M., and Borst, P., Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell, 77, 491-502 (1994).
30. Schutz, M. and Friedel, P., Isolation and cultivation of endothelial cells derived from human placenta. Eur. J. Cell Biol., 71, 395-401 (1996).
31. Sparreboom, A., Van Asperen, J., Mayer, U., Schinkel, A. H., Smit, J. W., Meijer, D. K., Borst, P., Nooijen, W. J., Beijnen, J. H., and van Tellingen, O., Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci., 94, 2031-2035 (1997).
32. Speeg, K. V. and Maldonodo, A. L., Effect of nonimmuno-suppressive cyclosporin analog SDZ PSC-833 on colchicine and doxorubicin biliary secretion by the rat in vivo. Cancer Chemother. Pharmacol., 34, 133-136 (1994).
33. Tanigawara, Y., Okamura, N., Hirai, M., Yasuhara, M., Ueda, K., Kioka, N., Komano, T., and Hori, R., Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC_PH1). J. Pharmacol. Exp. Ther., 263, 840-845 (1992).
34. Tatsura, T., Naito, M., Oh-hara, T., Sugawara, I., and Tsutuo, T., Functional involvement of P-glycoprotein in Blood-brain barrier. J. Biol. Chem., 276, 20383-20391 (1992).
35. Teifel, M. and Friedel, P., Establishment of the permanent microvascular endothelial cell line PBMEC/C1-2 from porcine brains. Exper. Cell Res., 338, 50-57 (1996).
36. Tsuji, A., Terasaki, T., Takabatake, Y., Tenda, Y., Tamai, I., Yamashima, T., Moritani, S., Tsuruo, T., and Yamashida, J., P-glycoprotein as the drug efflux pump in primary bovine capillary endothelial cells. Life Sci., 51, 1427-1437 (1992).
37. Van Asperen, J., Van Tellingen, O., Sparreboom, A., Schinkel, A. H., Borst, P., Nooijen, W. J., and Beijnen, J. H., Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC833. Br. J. Cancer, 76, 1181-1185 (1997).
38. th Scientific Meeting, p. 66 (2000).
39. 5]enkephalin opioid analogs. J. Pharmacol. Exper. Ther., 266, 1649-1655 (1993).